Perkins Coie Trust Company’s Bristol-Myers Squibb BMY Stock Holding History

Perkins Coie Trust Company’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-32	Closed	-$1.48K	–	297
2025 Q2	$1.48K	Sell	32 -6	-16%	-$295	﹤0.01%	270
2025 Q1	$2.32K	Buy	38 +6	+19%	+$350	﹤0.01%	281
2024 Q4	$1.81K	Hold	32	–	–	﹤0.01%	264
2024 Q3	$1.66K	Hold	32	–	–	﹤0.01%	272
2024 Q2	$1.33K	Hold	32	–	–	﹤0.01%	265
2024 Q1	$1.74K	Hold	32	–	–	﹤0.01%	227
2023 Q4	$1.64K	Sell	32 -205	-86%	-$10.8K	﹤0.01%	236
2023 Q3	$13.8K	Buy	237 +32	+16%	+$1.96K	﹤0.01%	204
2023 Q2	$13.1K	Hold	205	–	–	﹤0.01%	171
2023 Q1	$14.2K	Hold	205	–	–	﹤0.01%	180
2022 Q4	$14.7K	Hold	205	–	–	﹤0.01%	171
2022 Q3	$15K	Hold	205	–	–	0.01%	177
2022 Q2	$16K	Hold	205	–	–	0.01%	172
2022 Q1	$15K	Hold	205	–	–	﹤0.01%	192
2021 Q4	$13K	Sell	205 -38	-16%	-$2.23K	﹤0.01%	186
2021 Q3	$14K	Sell	243 -40	-14%	-$2.63K	﹤0.01%	195
2021 Q2	$19K	Buy	283 +38	+16%	+$2.48K	0.01%	198
2021 Q1	$15K	Sell	245 -34	-12%	-$2.12K	0.01%	195
2020 Q4	$17K	Sell	279 -1,314	-82%	-$80.8K	0.01%	195
2020 Q3	$96K	Sell	1,593 -1,920	-55%	-$116K	0.04%	111
2020 Q2	$207K	Sell	3,513 -400	-10%	-$23.9K	0.09%	97
2020 Q1	$218K	Buy	3,913 +340	+10%	+$20.8K	0.11%	89
2019 Q4	$229K	Buy	3,573 +264	+8%	+$15.1K	0.09%	94
2019 Q3	$168K	Buy	3,309 +1,600	+94%	+$75.2K	0.07%	97
2019 Q2	$77K	Sell	1,709 -600	-26%	-$27.9K	0.04%	136
2019 Q1	$110K	Hold	2,309	–	–	0.05%	110
2018 Q4	$120K	Hold	2,309	–	–	0.06%	107
2018 Q3	$143K	Hold	2,309	–	–	0.07%	106
2018 Q2	$128K	Sell	2,309 -775	-25%	-$41.9K	0.06%	111
2018 Q1	$195K	Hold	3,084	–	–	0.1%	94
2017 Q4	$189K	Hold	3,084	–	–	0.09%	95
2017 Q3	$197K	Hold	3,084	–	–	0.1%	94
2017 Q2	$172K	Buy	3,084 +775	+34%	+$42.2K	0.09%	97
2017 Q1	$126K	Hold	2,309	–	–	0.07%	94
2016 Q4	$135K	Buy	2,309 +70	+3%	+$3.83K	0.08%	92
2016 Q3	$121K	Buy	2,239 +68	+3%	+$4.37K	0.08%	93
2016 Q2	$160K	Hold	2,171	–	–	0.11%	86
2016 Q1	$139K	Hold	2,171	–	–	0.09%	85
2015 Q4	$149K	Hold	2,171	–	–	0.11%	77
2015 Q3	$129K	Hold	2,171	–	–	0.1%	79
2015 Q2	$144K	Hold	2,171	–	–	0.11%	80
2015 Q1	$140K	Buy	2,171 +1,204	+125%	+$75.4K	0.11%	79
2014 Q4	$57K	Sell	967 -500	-34%	-$28.2K	0.05%	112
2014 Q3	$75K	Hold	1,467	–	–	0.06%	97
2014 Q2	$71K	Hold	1,467	–	–	0.07%	93
2014 Q1	$76K	Buy	1,467 +300	+26%	+$16K	0.07%	88
2013 Q4	$62K	Buy	+1,167	New	+$59.4K	0.06%	97

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Perkins Coie Trust Company's BMY Position: Q3 2025 in Review

Perkins Coie Trust Company sold out of Bristol-Myers Squibb (BMY) in Q3 2025, closing a stake of 32 shares — an estimated $1.48K sold.

Perkins Coie Trust Company first reported a position in BMY in Q4 2013 and held it in 47 quarters. The position peaked at $229K in Q4 2019. 2,276 funds tracked by Wall St. Rank hold BMY as of Q3 2025.

Perkins Coie Trust Company reported no remaining Bristol-Myers Squibb position as of Q3 2025 after selling out during the quarter.
Perkins Coie Trust Company sold 32 Bristol-Myers Squibb shares in Q3 2025, an estimated $1.48K.
Perkins Coie Trust Company first reported a position in Bristol-Myers Squibb in Q4 2013 and held it in 47 quarters.
Perkins Coie Trust Company's Bristol-Myers Squibb position peaked at $229K in Q4 2019.
2,276 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.

Based on Perkins Coie Trust Company's 13F filing for Q3 2025, filed 9 Oct 2025.